Thiadiazoles as CXC- and CC- chemokine receptor ligands

US7786149B2 · kind B2 · utility

Assignees

• SCHERING CORPORATION · US
• Pharmacopeia Drug Discovery, Inc. · US

Inventors

• Purakkattle Biju · Piscataway, US
• Arthur G. Taveras · Rockaway, US
• J. Merritt · Ewing, US
• John J. Baldwin · Gwynedd Valley, US
• Younong Yu · East Brunswick Township, US
• Junying Zheng · New Providence, US
• Jianhua Chao · Pompton Lakes, US
• Cynthia Aki · Livingston, US

Key dates

• Filing date: Sep 26, 2007
• Grant date: Aug 31, 2010
• Expiry date: Sep 26, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are novel compounds of the formula:and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and ischemia reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.